Clinical Trial Update: Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pyrotinib combined with trastuzumab, dalpiciclib, and letrozole for HR+/HER2+ breast cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Letrozole (letrozole)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Yantai Yuhuangding Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN